Gregory A. Fechner

Suggest Changes
Learn More
BACKGROUND The second-line chemotherapeutic treatment for metastatic urothelial cancer (UC) after failure of cisplatin-based first-line therapy needs to be improved. Based on encouraging phase II(More)